Advertisement
Australia markets open in 21 minutes
  • ALL ORDS

    7,908.10
    +8.90 (+0.11%)
     
  • AUD/USD

    0.6542
    -0.0021 (-0.32%)
     
  • ASX 200

    7,652.80
    +9.20 (+0.12%)
     
  • OIL

    77.60
    +1.11 (+1.45%)
     
  • GOLD

    2,040.90
    -8.50 (-0.41%)
     
  • Bitcoin AUD

    83,375.38
    +4,082.19 (+5.15%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

INSPECS Group First Half 2023 Earnings: EPS: UK£0.02 (vs UK£0.022 loss in 1H 2022)

INSPECS Group (LON:SPEC) First Half 2023 Results

Key Financial Results

  • Revenue: UK£111.2m (up 1.6% from 1H 2022).

  • Net income: UK£2.08m (up from UK£2.20m loss in 1H 2022).

  • Profit margin: 1.9% (up from net loss in 1H 2022).

  • EPS: UK£0.02 (up from UK£0.022 loss in 1H 2022).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

INSPECS Group Earnings Insights

Looking ahead, revenue is expected to decline by 1.4% p.a. on average during the next 3 years, while revenues in the Medical Equipment industry in the United Kingdom are expected to grow by 6.3%.

Performance of the British Medical Equipment industry.

The company's shares are up 5.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on INSPECS Group's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.